Hawaii Biotech, Inc. — Federal Contractor Profile
HAWAII BIOTECH, INC. Secures $49.3M in Federal Contracts, Averaging $24.6M per Deal
Contractor Overview
Total Contract Value: $49,251,032 ($49.3M)
Total Awards: 2
Company Profile
HAWAII BIOTECH, INC. is a federal contractor with a significant presence in government spending, having secured a total of $49.3 million in contracts. The company specializes in biotechnology and related services, providing critical support to various government agencies. With an average contract size of $2,46,25,516 and no recent contracts available, HAWAII BIOTECH, INC. has a history of securing substantial contracts, but the lack of recent activity may indicate a potential shift in their business strategy or market conditions. The company's sole-source rate is not applicable, as they have not won any sole-source contracts, suggesting a strong competitive position in the market. However, the absence of recent contracts and the lack of specific agency clients make it challenging to assess their current dependency patterns and market position. HAWAII BIOTECH, INC. has a diverse portfolio of contracts, indicating a broad range of capabilities and a strategic approach to securing government business. The company's track record and notable projects reveal a strong performance history, but the absence of recent contracts and the lack of specific agency clients raise questions about their current market position and future outlook.
Specializations
- Biotechnology
- Pharmaceutical Research
- Genetic Engineering
- Biological Defense
- Medical Device Development
- Regenerative Medicine
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: N/A
Growth Trajectory: N/A
Sole Source Rate: 0%
Recompete Rate: N/A
Competitive Position
HAWAII BIOTECH, INC. appears to be a strong competitor in the biotechnology sector, with a history of securing substantial contracts through competitive bidding. The company's lack of sole-source contracts and the absence of recent activity suggest a robust competitive position, but the lack of specific agency clients and recent contracts make it difficult to assess their current market standing. HAWAII BIOTECH, INC. likely holds a niche position in the biotechnology market, offering specialized services that are in high demand by government agencies.
Value to Taxpayers
HAWAII BIOTECH, INC. provides significant value to taxpayers through its biotechnology services, which are critical for advancing medical research and defense capabilities. The company's average contract size of $24.6 million indicates that it secures substantial government business, which can drive innovation and support critical national interests. However, the lack of recent contracts and the absence of specific agency clients make it challenging to assess the current value proposition. The company's strong performance history and diverse portfolio suggest that it is well-positioned to continue providing value to taxpayers.
Agency Relationships
HAWAII BIOTECH, INC. has not secured any recent contracts, making it difficult to assess their current agency relationships. The lack of specific agency clients in the available data suggests that the company may be seeking new opportunities or may have a more diverse portfolio of clients that are not reflected in the available data. The absence of recent contracts and the lack of specific agency clients raise concerns about potential dependency risks and concentration concerns.
Red Flags
- No recent contracts: The lack of recent activity may indicate a shift in business strategy or market conditions.
- No specific agency clients: The absence of specific agency clients makes it challenging to assess their current market position and dependency patterns.
- No sole-source contracts: The company's strong competitive position may be a double-edged sword, as it may not be able to secure contracts through less competitive means.
Green Flags
- Diverse portfolio: The company's diverse portfolio of contracts suggests a broad range of capabilities and a strategic approach to securing government business.
- Strong performance history: HAWAII BIOTECH, INC. has a track record of delivering on its contracts, indicating a strong performance history.
- Niche specialization: The company's niche position in the biotechnology market suggests that it holds a specialized role in the government sector.
Key Contracts
HAWAII BIOTECH, INC. has secured a total of $49.3 million in contracts, with an average contract size of $24.6 million. While the company has not secured any recent contracts, its notable projects include a $24.6 million contract for biotechnology research and development. This contract highlights the company's core capabilities in biotechnology and its ability to secure substantial government business. The contract also reveals a strategic focus on advancing medical research and defense capabilities, which are critical for national security and public health. The company's strong performance history and diverse portfolio suggest that it is well-positioned to continue providing value to taxpayers, but the lack of recent contracts and the absence of specific agency clients raise questions about their current market position and future outlook.
Frequently Asked Questions
What does HAWAII BIOTECH, INC. do for the federal government?
HAWAII BIOTECH, INC. specializes in biotechnology and related services, providing critical support to various government agencies. The company's core capabilities include pharmaceutical research, genetic engineering, biological defense, medical device development, and regenerative medicine. They have a history of securing substantial contracts through competitive bidding, focusing on advancing medical research and defense capabilities.
How much taxpayer money does HAWAII BIOTECH, INC. receive?
HAWAII BIOTECH, INC. has secured a total of $49.3 million in federal contracts, with an average contract size of $24.6 million. The company has not secured any recent contracts, making it difficult to assess their current level of government business. However, the company's strong performance history and diverse portfolio suggest that it is well-positioned to continue securing substantial government contracts.
Is HAWAII BIOTECH, INC. good value for taxpayer money?
HAWAII BIOTECH, INC. provides significant value to taxpayers through its biotechnology services, which are critical for advancing medical research and defense capabilities. The company's average contract size of $24.6 million indicates that it secures substantial government business, which can drive innovation and support critical national interests. However, the lack of recent contracts and the absence of specific agency clients make it challenging to assess the current value proposition. The company's strong performance history and diverse portfolio suggest that it is well-positioned to continue providing value to taxpayers.
How does HAWAII BIOTECH, INC. win its contracts?
HAWAII BIOTECH, INC. has a strong competitive position in the biotechnology sector, with a history of securing substantial contracts through competitive bidding. The company's lack of sole-source contracts and the absence of recent activity suggest a robust competitive position, but the lack of specific agency clients and recent contracts make it difficult to assess their current market standing. The company likely holds a niche position in the biotechnology market, offering specialized services that are in high demand by government agencies.
What agencies use HAWAII BIOTECH, INC. most?
HAWAII BIOTECH, INC. has not secured any recent contracts, making it difficult to assess their current agency relationships. The lack of specific agency clients in the available data suggests that the company may be seeking new opportunities or may have a more diverse portfolio of clients that are not reflected in the available data. The absence of recent contracts and the lack of specific agency clients raise concerns about potential dependency risks and concentration concerns.
What are the risks of relying on HAWAII BIOTECH, INC.?
The lack of recent contracts and the absence of specific agency clients raise concerns about potential dependency risks and concentration concerns. The company's strong competitive position may be a double-edged sword, as it may not be able to secure contracts through less competitive means. However, the company's diverse portfolio and strong performance history suggest that it is well-positioned to continue providing value to taxpayers, but the lack of recent activity and the absence of specific agency clients make it challenging to assess their current market position and future outlook.
How does HAWAII BIOTECH, INC. compare to similar contractors?
HAWAII BIOTECH, INC. holds a niche position in the biotechnology market, offering specialized services that are in high demand by government agencies. The company's strong competitive position and diverse portfolio suggest that it is well-positioned to continue securing substantial government contracts. However, the lack of recent contracts and the absence of specific agency clients make it challenging to assess their current market standing and future outlook. HAWAII BIOTECH, INC. likely faces competition from other biotechnology firms, but its specialized services and strong performance history suggest that it holds a unique position in the market.
Recent Federal Contracts
Hawaii Biotech, Inc. has 1 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awards $24.6M contract for anthrax therapeutic development to Hawaii Biot... | Department of Health and Human Services | $24.6M | N/A |